In a significant step toward transforming pediatric critical care, Aster CMI Hospital today announced the launch of PEARL (Pediatric Emergency and Advanced Response for Liver Care) – Karnataka’s first dedicated Pediatric Liver Intensive Care Unit...
Indian oncology medicine manufacturers are witnessing a clear disconnect between rapid scientific innovation — including targeted therapies, biosimilars, next-generation sequencing (NGS), minimal residual disease assays, and immuno-oncology treatm...
OneSource Speciality Pharma has said that its partner, Orbicular Pharmaceutical Technologies, along with a US-based front-end partner, has received tentative approval from the U.S. Food and Drug Administration for a generic version of semaglutid...
Morepen Laboratories Limited has once again strengthened its reputation for quality standards and regulatory compliance by clearing a USFDA inspection with nil adverse observations. This marks the fourth consecutive time that the company’s Masulak...
AstraZeneca said its experimental drug tozorakimab cuts COPD flare-ups in patients with chronic obstructive pulmonary disease (COPD) in a Phase III trial, meeting the study’s primary goal. The tozorakimab results showed a significant drop in...
India is facing a serious thalassemia drug shortage, prompting the government to seek an explanation from Novartis while exploring generic alternatives to stabilize supply. The issue centers on Desferal, a life-saving treatment used by...
India is facing a growing public health concern as energy drinks are increasingly being linked to liver damage in young adults. Doctors across the country report a noticeable rise in patients in their 20s and 30s showing early signs of liver...
A Gujarat-based non-governmental organisation has called on the Centre to bring nutraceuticals regulation India under stricter drug control, raising concerns about product quality issues, consumer safety risks, and pricing concerns in healthca...
Rusan Pharma has achieved a significant global milestone by receiving Good Manufacturing Practice (GMP) approval from Pharmaceuticals and Medical Devices Agency (PMDA), one of the world’s most stringent drug regulators.
Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics in a deal valued at more than $2 billion, signaling a strong push into next-generation cancer treatments.